Actively Recruiting
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Led by Deciphera Pharmaceuticals, LLC · Updated on 2025-11-05
100
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
CONDITIONS
Official Title
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Tenosynovial Giant Cell Tumor (TGCT) according to medical records
- Prescribed vimseltinib per approved label requirements
- Either have not started vimseltinib treatment yet or have received the first dose less than 6 months before enrollment
- Provided informed consent and medical records release
You will not qualify if you...
- Received any other systemic agent for TGCT treatment during the 6 months before starting vimseltinib
- Received the first dose of vimseltinib in the current treatment course more than 6 months before enrollment
- Currently active in an interventional clinical trial of vimseltinib
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Synexus Clinical Research, US INC
Wilmington, North Carolina, United States, 28401
Actively Recruiting
Research Team
C
Clinical Team
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here